We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
In the latest close session, Viking Therapeutics, Inc. (VKTX - Free Report) was down 4.23% at $32.80. The stock trailed the S&P 500, which registered a daily loss of 0.41%. Meanwhile, the Dow experienced a drop of 0.36%, and the technology-dominated Nasdaq saw a decrease of 0.89%.
The stock of company has risen by 3.16% in the past month, leading the Medical sector's gain of 0.47% and undershooting the S&P 500's gain of 9.71%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company's earnings report is expected on April 29, 2026. The company is predicted to post an EPS of -$0.95, indicating a 131.71% decline compared to the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$3.78 per share and a revenue of $0 million, indicating changes of -18.5% and 0%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Viking Therapeutics, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 8.99% rise in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 143, this industry ranks in the bottom 42% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
In the latest close session, Viking Therapeutics, Inc. (VKTX - Free Report) was down 4.23% at $32.80. The stock trailed the S&P 500, which registered a daily loss of 0.41%. Meanwhile, the Dow experienced a drop of 0.36%, and the technology-dominated Nasdaq saw a decrease of 0.89%.
The stock of company has risen by 3.16% in the past month, leading the Medical sector's gain of 0.47% and undershooting the S&P 500's gain of 9.71%.
The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company's earnings report is expected on April 29, 2026. The company is predicted to post an EPS of -$0.95, indicating a 131.71% decline compared to the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$3.78 per share and a revenue of $0 million, indicating changes of -18.5% and 0%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Viking Therapeutics, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 8.99% rise in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 143, this industry ranks in the bottom 42% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.